The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer

Arianna Giacomini(University of Brescia), Roberto Ronca(Brescia University)

Experimental Hematology and Oncology

September 25, 2023

10.1186/s40164-023-00441-y

Cited by 13

Related Papers

Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia

|Cancer|2011|28

Concurrent RB1 and P53 pathway disruption predisposes to the development of a primitive neuronal component in high-grade gliomas depending on MYC-driven EBF3 transcription

|Acta Neuropathologica|2025|6

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.

|Blood|2010|1